PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Summary

The purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System) in patients with biopsy-confirmed, human papilloma virus (HPV) 16-associated high grade cervical intraepithelial neoplasia (CIN2/3) as compared to the administration of placebo.

Timeline

Start

2026-04-01

Primary completion

2027-12

Completion

2028-06

Drugs

Indications